On February 28 the US Food and Drug Administration took the unprecedented step of seizing stocks of Peritrate SA (Warner-Chileott Labs), a sustained-action preparation of pentaerythritol tetranitrate. This was done because the FDA judged advertisements for the drug to be ‘false and misleading’. They implied that the drug increased survival after myocardial infarction by asking ‘Is Peritrate life - sustaining?’, clearly inviting the answer ‘yes’.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.